Background and aims: Alteration in intestinal permeability is the main factor underlying the pathogenesis of many diseases affecting the gut, such as inflammatory bowel disease [IBD]. Characterization of molecules targeting the restoration of intestinal barrier integrity is therefore vital for the development of alternative therapies. The yeast Saccharomyces boulardii CNCM I-745 [Sb], used to prevent and treat antibiotic-associated infectious and functional diarrhea, may have a beneficial effect in the treatment of IBD. Methods: We analyzed the impact of Sb supernatant on tissue integrity and components of adherens junctions using cultured explants of colon from both IBD and healthy patients. To evaluate the pathways by which Sb regulates the expression of E-cadherin at the cell surface, we developed in vitro assays using human colonic cell lines, including cell aggregation, a calcium switch assay, real-time measurement of transepithelial electrical resistance [TEER] and pulse-chase experiments. Results: We showed that Sb supernatant treatment of colonic explants protects the epithelial morphology and maintains E-cadherin expression at the cell surface. In vitro experiments revealed that Sb supernatant enhances E-cadherin delivery to the cell surface by re-routing endocytosed E-cadherin back to the plasma membrane. This process, involving Rab11A-dependent recycling endosome, leads to restoration of enterocyte adherens junctions, in addition to the overall restoration and strengthening of intestinal barrier function.
Saccharomyces boulardii

Introduction
The colonic epithelium forms a continuous physical and functional barrier that protects the internal environment of the body from fluctuating external milieu. Intestinal barrier defects, followed by permeation of luminal noxious molecules, induce a perturbation of the mucosal immune system and inflammation. This permeability alteration causes a defect in the intestinal epithelial barrier that is the basis for the pathogenesis of many diseases affecting the gut, such as infectious enterocolitis, small intestinal bacterial overgrowth, inflammatory bowel disease [IBD] and irritable bowel syndrome [IBS] . 1, 2 Intestinal paracellular permeability and barrier integrity are regulated by apical junctional complexes, comprised of tight junctions and adherens junctions. 3 During episodes of inflammation, these apical junctional complexes in the gut are often compromised, increasing epithelial permeability.
The tight junction is the most apical component of these junctional complexes, sealing the intercellular space between adjacent epithelial intestinal cells. Tight junctions also regulate selective paracellular transport of ions and solutes and prevent the translocation of microorganisms and antigens across the epithelium. Previous reports have described alterations in tight junction integrity in patients suffering from IBD and IBS. 2, [4] [5] [6] [7] Apart from disruption of tight junctions, another important factor known to regulate intestinal permeability is the adherens junction. Adherens junctions are located immediately below the tight junction, providing a dynamic adhesive connection between epithelial cells. In the intestinal epithelium, the transmembrane glycoprotein E-cadherin is a major component of the adherens junction. E-cadherin possesses an extracellular region that facilitates homophilic ligation with cadherins present on adjacent cells. The cytoplasmic tail of E-cadherin contains binding regions for p120 catenin [p120 ctn] at the juxtamembrane domain and for either β-catenin or γ-catenin at the C-terminal catenin binding domain. Both domains are thought to be involved in regulating the adhesive properties of E-cadherin. p120 ctn regulates E-cadherin stability 8 while β-catenin, which further associates with α-catenin, modulates functional interactions with the actin cytoskeleton.
5 These E-cadherin-mediated cell-cell adhesions are crucial for the assembly and stability of tight junctions. Modification of E-cadherin-dependent adherens junctions could therefore affect intestinal epithelial paracellular permeability. 5 A large body of evidence suggests a role for the E-cadherin/catenin complex in both IBD and IBS. 9 In particular, reduced expression and/ or mislocation of E-cadherin was found during the course of IBD and IBS. [9] [10] Moreover, E-cadherin seems to be a target of signaling pathways during infections involving an increase in intestinal permeability. 11 Overall, the assessment of molecules involved in the restoration of adherens junctions could lead to the development of drugs for treating many diseases affecting intestinal permeability.
Previous reports suggest that administration of probiotics can improve intestinal permeability. 12, 13 The probiotic yeast Saccharomyces boulardii CNCM I-745 [Sb] is widely used in a lyophilized form for treating and preventing antibiotic-associated and infectious diarrhea.
14 Both in vitro and in vivo studies indicate that Sb interacts with pathogenic microorganisms and resident microflora, as well as intestinal mucosa. 15, 16 In addition, clinical trials have suggested that Sb can be effective in the treatment of IBD and IBS via modulation of host cell signaling pathways implicated in the pro-inflammatory response and/or regulation of epithelial barrier integrity. 12, 17 Moreover, Sb protects the intestinal barrier in enteropathogenic E. coli-associated colitis. 18 Our aim was to decipher the mechanisms by which Sb may modulate intestinal permeability and adherens junction components. We utilized cultured explants of colons from IBD patients to analyze the impact of Sb on components of adherens junctions as well as on tissue integrity. We also developed in vitro assays using human colonic cell lines to evaluate the molecular pathways by which Sb regulates the expression of the E-cadherin/catenin complex at the cell surface.
Materials and Methods
Patients and ethics statements
Colon specimens were obtained from 10 patients who failed treatment of chronic ulcerative colitis [ 
Explant cultures
The mucosa of colon specimens was carefully stripped from the underlying compartment comprised of the muscularis mucosae and the submucosa. The mucosal tissue was divided into two parts: one part was paraffin-embedded for staining; the second part was cut into 1 mm3 pieces and transferred to Millicell cell culture inserts [porosity: 0.4µm; Millipore, Molsheim, France]. Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal calf serum [FCS] plus Saccharomyces cerevisiae supernatant (ScS) or Saccharomyces boulardii supernatant (SbS) was placed in both the lower and upper chambers. Explants were maintained at 37°C and 5% CO 2 and cultured from 24 to 72 h. Explants were paraffin-embedded, and tissue integrity was assessed by standard morphological analysis using hematoxylin staining on paraffin sections [ Figure S1 ].
Cell culture
The human colonic adenocarcinoma cell line HCT-8/E11 was routinely cultured as previously described. 19 Cells were cultured in DMEM containing 10% FCS at 37°C in a 5% CO 2 atmosphere until they reached confluency. These cellular monolayers consist of polarized cells joined by tight junctions, which exhibit well-developed apical microvilli, allowing the study of processes involved in intestinal epithelial cell physiology. 16, 19, 20 E-cadherin was stably knocked down in HCT-8/E11 cells by RNA interference using Mission shRNA lentiviral particles [Sigma, Saint Quentin Fallavier, France]. Two lentiviral transduction particles [TRCN0000237840 and TRCN0000237843] were chosen for E-cadherin along with a negative control [SHC002V] . Cells were infected with lentiviral particles according to the manufacturer's instructions. shRNA-containing cells were selected with 5 µg/mL puromycin and cloned by an end-point dilution assay. Cells were harvested to assess E-cadherin expression by western blotting [ Figure S2 ] and to perform functional assays.
HCT-8/E11 cells were stably transfected with E-cadherin-GFP as previously reported for MDCK cells 21 and routinely cultured in 600 µg/mL geneticin [Sigma] . Cell surface E-cadherin-GFP expression was assessed using an Olympus IX83 inverted microscope in a temperature-and CO 2 -controlled chamber.
Rab11A 
Pulse chase assay
Cells were incubated for 1 h at 4°C with 5 µg/mL mouse anti-Ecadherin [clone HECD-1; Takara] to label E-cadherin expressed at the cell surface. The antibody was then washed out with cold phosphate-buffered saline [PBS] , and cells incubated in DMEM containing 0.1% BSA [w/v] plus ScS or SbS for 30 min at 37°C. Cells were washed on ice with PBS containing 10 mM azide, 0.5 M acetic acid and 0.5 M NaCl to remove labeled E-cadherin localized at the cell surface. Cells were then fixed in 2% formaldehyde and subjected to either immunofluorescence or proximity ligation analysis [PLA].
Immunofluorescence
Cell monolayers were fixed for 20 min with 2% formaldehyde in PBS and permeabilized with 0.1% saponin in PBS for 15 min. 
Proximity ligation analysis
Transepithelial electrical resistance
Confluent cell monolayers cultured on the top of cell culture inserts were incubated in SMEM for 1 h, then incubated in DMEM containing 0.1% BSA in the presence of either ScS or SbS. Measurement of transepithelial electrical resistance [TEER] was performed every 20 min for 48 h using a CellZscope apparatus [nanoAnalytics] as previously described. 
Western blotting
Western blotting experiments, performed on either cell or human colonic mucosa lysates, were performed as previously described. 16, 22, 23 Immunoreactive bands were detected using Syngene PXi apparatus [Millipore, France].
Fluorescence recovery after photobleaching
HCT-8/E11 cells expressing E-cadherin-GFP were placed in DMEM (without phenol red) containing 0.1% BSA and either ScS or SbS, then maintained at 37°C by a heating frame. Fluorescence recovery after photobleaching [FRAP] experiments were performed using an SP5 Leica confocal microscope. Each experiment started with two image scans, followed by a series of five bleach pulses, every 0.198 ms with a 2 µm radius circular area of the membrane using the 488 nm wavelength laser at 44% power. Subsequently, a series of 60 single-section images were collected over 11.88 s. We measured ~20 separate FRAP measurements in five independent experiments, and curves were independently double-normalized according to the method of Phair et al. 24 and as previously described.
25,26
Statistics
Data are presented as the mean ± S.D. for three independent experiments performed in triplicate. Comparisons between two conditions were made using the Mann-Whitney test; p < 0.05 was considered statistically significant in all analyses. Three asterisks indicated p < 0.001, two asterisks p < 0.01 and one asterisk p < 0.05.
Results
SbS maintained both E-cadherin and p120 ctn expression at intercellular contacts
We first analyzed E-cadherin expression in both IBD and non-IBD patients. In accordance with previous studies, 27, 10 we observed that E-cadherin expression is reduced in tissues from IBD patients compared with healthy tissues [ Figure 1A ]. The adherens junction proteins E-cadherin, p120 ctn and β catenin are uniformly localized at the intercellular borders of epithelial cells within normal colonic mucosa. However, we observed a reduced membranous expression of both E-cadherin and p120 ctn in the colonic mucosa of IBD patients [ Figure 1B ]. Moreover, as well as a partial downregulation, both E-cadherin and p120 ctn were partially redistributed into the cytoplasm within the colonic mucosa of both UC and CD patients, indicating a perturbation of the intestinal barrier in IBD. However, we found neither a reduced expression nor mislocalization of β catenin [data not shown].
To explore the impact of Sb on adherens junction proteins, human colonic mucosa samples from IBD patients undergoing surgery were cultured for 48 h in the presence of either SbS or ScS, a yeast control that does not impact intestinal epithelial cell physiology. 16, 20 As assessed by immunofluorescence, explants cultured in the presence of SbS displayed higher levels of E-cadherin and p120 ctn staining than cells cultured with ScS [ Figure 2 ]. In addition, both E-cadherin and p120 ctn localized at the lateral cell membranes in SbS-treated cells. Conversely, SbS did not regulate localization or fluorescence intensity of either adherens junction protein in healthy colonic mucosa. β catenin was found at the intercellular junctions of epithelial cells regardless of culture conditions [data not shown].
Altogether these results suggest that SbS maintains both E-cadherin and p120 ctn at intercellular contacts.
SbS strengthened E-cadherin-dependent adhesion
To decipher the molecular pathways by which SbS regulates cell surface expression of the E-cadherin/catenin complex, we used the human colonic HCT-8/E11 cell line that exhibits functional adherens junctions. 19 When cultured in suspension, these cells spontaneously form aggregates. The aggregates formed by stably knocked-down E-cadherin HCT-8/E11 cells were less compact, indicating that this cell aggregation is E-cadherin-dependent [ Figure 3A ]. The aggregates became more compact when HCT-8/ E11 cells were cultured with SbS. Moreover, SbS did not counteract the effect of E-cadherin depletion. These data strongly suggest that SbS acts on cell-cell adhesion depending on adherens junction molecules.
Incubation of cells in calcium-free SMEM resulted in a loss of membranous E-cadherin and a reduction in p120 ctn expression [ Figure 3B ]. In addition, E-cadherin staining was maintained at the cell surface when cells were incubated in calcium-free medium containing dynasore, a dynamin inhibitor, suggesting that dynamin participates in the endocytosis of the E-cadherin/catenin complex [ Figure S3 ]. The return of calcium resulted in recovery of E-cadherin at the cell surface. However, the extent of recovery was significantly increased in SbS-treated cells compared with ScS-treated cells [ Figure 3B ]. The increased E-cadherin recovery at the cell membrane was associated with a reorganization of F-actin at cell-cell contact sites [ Figure 3C ].
SbS treatment increased recovery in permeability of the paracellular barrier
Cell-cell contacts were dramatically altered when HCT-8/E11 cells were incubated in SMEM [ Figure 4A ], and the morphology of the monolayer was similar to E-cadherin-depleted cells [ Figure S4 ]. We examined the time-course of cell-cell contact recovery in both SbSand ScS-treated cells. Recovery significantly increased in SbS-treated cells relative to ScS-treated cells [ Figure 4A ]. However, SbS treatment was inefficient on E-cadherin-depleted cells.
To confirm this impact on cell-cell contacts, we sought to determine whether SbS regulates intestinal epithelial barrier function. HCT-8/E11 cells incubated with SbS after calcium depletion promoted a significant increase in TEER compared with ScS-treated cells [ Figure 4B ]. It should be noted that SbS did not modulate the TEER of E-cadherin-depleted cells. Interestingly, the increase in TEER was associated with a reduced permeability of HCT-8/E11 monolayers to FITC-dextran [ Figure 4C ]. SbS maintained both E-cadherin and p120 ctn expression at intercellular contacts in cultured explants of colonic mucosa. Explants of colonic mucosa issued from the same tissues of non-IBD, CD or UC patients were cultured in the presence of SbS or ScS for 48 h. Explants were collected and paraffinembedded. Paraffin sections were subjected to E-cadherin or p120 ctn staining. Fluorescence intensities from four healthy tissues, four CD patient tissues and four UC patient tissues were measured using ImageJ software. Scale bar: 25µm.
Altogether, these results indicate that SbS restores and strengthens intestinal barrier function.
SbS accelerated E-cadherin recycling
We next evaluated how SbS regulates membranous E-cadherin expression. Using a human qPCR array and RT-qPCR experiments, we observed that SbS did not regulate the mRNA expression of adherens junction molecules [ Figure 5A , 5B and S5]. In addition, western blot analysis indicated that SbS did not affect E-cadherin expression levels [ Figure 5C ]. Moreover, cycloheximide, an inhibitor of protein synthesis, did not counteract the effect of SbS on E-cadherin recovery at the cell surface [ Figure S6 ]. However, flow [B] E-cadherin and p120 ctn were immunostained and revealed with Alexa 488-conjugated goat anti-mouse. Scale bar: 25µm.
[C] Actin was detected using TRITC-phalloidin by confocal acquisitions. Scale bar: 20µm. Immunostaining intensities were measured using ImageJ software.
cytometry analysis showed that cell treatment with SbS after calcium depletion enhanced E-cadherin expression at the cell surface [ Figure 5D ]. Altogether, these results suggest that SbS regulates E-cadherin remodeling at the cytoplasmic cell membrane.
To confirm this hypothesis, we first explored the effect of Golgicide A, a specific inhibitor of cis-golgi function, which arrests secretion of soluble and membrane-associated proteins at the endoplasmic reticulum -Golgi intermediate compartment. Interestingly, this compound did not counteract the effect of SbS on E-cadherin recovery at the cell surface [ Figure S6 ], indicating that SbS does not regulate the traffic of newly synthesized E-cadherin within the Golgi apparatus.
Second, we analyzed the impact of SbS on the mobility of E-cadherin within the plasma membrane. FRAP experiments were performed using GFP-E-cadherin-expressing cells in the presence of either SbS or ScS. As observed in Table 1 , SbS treatment did not modify FRAP recovery of GFP-E-cadherin, indicating that SbS does not alter the lateral mobility of E-cadherin within the plasma membrane.
Modulation of molecule recycling is another possible explanation for the regulation of E-cadherin delivery to the plasma membrane. Therefore, we analyzed the fate of E-cadherin following its endocytosis. Calcium depletion led to E-cadherin internalization from the cell membrane to intracellular vesicles [ Figure 5E ]. Notably, we discovered that SbS promoted a rapid relocalization of internalized E-cadherin to vesicles located at the cell membrane periphery, unlike cells treated with ScS [ Figure 5F ].
SbS-induced E-cadherin recycling was dependent on Rab11A
Rab GTPases are well recognized targets in human disease. 28, 29 Since Rab GTPases Rab4 and Rab11A represent early and recycling endosome markers, respectively, 30, 31 we sought to determine whether SbS enhanced E-cadherin traffic to recycling endosomes. Immunofluorescence analysis revealed that SbS, unlike ScS, promoted colocalization between Rab11A and E-cadherin in a proportion of vesicles located at the cell membrane periphery [ Figure 6A ]. However, E-cadherin did not colocalize with Rab4, regardless of the condition tested [ Figure 6A ]. We confirmed these observations using in situ PLA [ Figure 6B ]. Altogether, these results suggest that SbS enhances the recycling of E-cadherin to Rab11A-dependent recycling endosomes. To further confirm such a possibility, Rab11A was transiently downregulated using an siRNA interference strategy. Rab11A deletion impaired E-cadherin delivery to the cell membrane, indicating that in these cells, Rab11A promotes E-cadherin recycling to the cell membrane [ Figure S7 ]. Transfection with a scramble siRNA [siCTRL] did not counteract the effect of SbS. However, in the Rab11A-deficient cells, SbS failed to deliver endocytosed E-cadherin in the vesicles located at the cell periphery [ Figure 6C ]. Taken together these data indicate that SbS-induced E-cadherin recycling is dependent on Rab11A.
Discussion
Extensive research has shown that a number of different intestinal diseases, including infectious diarrhea, IBS, IBD and celiac disease, are associated with alterations in the intestinal barrier. 13 This failure enables access of luminal content to underlying tissue, initiating an inflammatory cascade. Therefore, the characterization of molecules that restore intestinal barrier integrity is crucial for the development of alternative therapies. Accordingly, several studies have highlighted the role of molecules such as INFγ, EGF, TNF-α or probiotics in the regulation of intestinal permeability. 2, 32 Here, we analyzed whether Sb, a nonpathogenic yeast, was able to restore an altered intestinal barrier. To achieve this, we used a calcium switch [E] Cells were incubated for 1 h at 4°C with anti-E-cadherin to label E-cadherin expressed at the cell surface [CTRL condition]. Cells were incubated at 37°C for 1 h in SMEM, then incubated for 30 min in DMEM plus ScS or SbS. After acidic treatment to remove labeled E-cadherin localized at the cell surface, cells were fixed and incubated with Alexa 488-conjugated goat anti-mouse to stain cytoplasmic labeled E-cadherin [white arrow]. Samples were observed with a confocal microscope. Scale bar: 12µm.
[F] Internalized E-cadherin found in large endocytic vesicles was quantified using ImageJ software. Results are expressed as percentage of cells that exhibit E-cadherin staining in endocytic vesicles. Data represent the mean of three independent experiments.
assay that mimics the process of junction disassembly observed in many pathophysiological conditions. 33 According to our findings, the impact of Sb on colonic mucosa can be summarized as follows: [i] SbS increases the cell surface expression of E-cadherin and the submembranous expression of p120 ctn, although does not modify their protein levels.
[ii] SbS enhances E-cadherin delivery to adherens junctions by re-routing E-cadherin back to the plasma membrane. This process is dependent on the Rab11A-dependent recycling endosome.
[iii] The regulation of E-cadherin trafficking strengthens the function of the intestinal barrier.
[iv] SbS maintains both E-cadherin and p120 ctn at intercellular contacts of cultured colonic mucosa from IBD patients.
Tight junctions, adherens junctions and desmosomes all ensure the integrity of the epithelial barrier. Clinical and experimental studies, including this work, indicate that defects in both tight junctions and adherens junctions are observed in various intestinal diseases. 2, [34] [35] Moreover, some enteric pathogens are capable of disturbing barrier function in epithelial cell models by directly affecting the stability of both tight junctions and adherens junctions. 36 Research on modulation of gut permeability mainly focuses on the ability of molecules to restore the stability of tight junctions rather than adherens junctions. 12, 36, 37 Previous studies have shown that SbS appears to strengthen enterocyte tight junctions. 12, 38 The aim of our study was to determine whether SbS targets adherens junction molecules. We showed in vitro that SbS restores and strengthens intestinal barrier function by modulating the E-cadherin/catenin complex. In summary: [i] SbS increased E-cadherin-dependent cell aggregation; [ii] video microscopy analysis revealed that SbS reorganizes E-cadherin-dependent cell-cell contacts; [iii] SbS accelerates, in an E-cadherin-dependent manner, the formation of the circumferential F-actin belt associated with cytosolic adherens junction plaques. The reorganization of this cytoskeletal structure is a crucial mechanism for regulating the integrity and remodeling of epithelial junctions 39 ;
[iv] SbS induced a significant increase in TEER and concomitantly reduced intestinal permeability by modulating the E-cadherin/ catenin complex. Moreover, E-cadherin-depleted cells were insensitive to SbS. As tight junctions are known to regulate paracellular trafficking of macromolecules, adherens junctions therefore provide mechanical adhesive strength for maintaining cell-cell contacts and enabling the assembly and stability of tight junctions. 40 According to this, by reorganizing E-cadherin-dependent cell-cell contacts, SbS could also strengthen enterocyte tight junctions. 12, 38 E-cadherin is present in two pools within the membrane: [i] diffusible E-cadherin molecules; [ii] transmembrane clusters engaged in cell-cell adhesion. The movement of E-cadherin molecules between these two pools governs the formation of stable junctions. 9 The mechanisms that regulate the movement of E-cadherin within the membrane are not fully understood, although our data suggest that SbS does not interfere with this mechanism. Indeed, FRAP experiments on GFP-E-cadherin-expressing cells indicated that SbS does not regulate the lateral movement of E-cadherin within the plasma membrane.
Our data demonstrate that SbS regulates E-cadherin trafficking rather than E-cadherin synthesis. Both RNA microarray and RT-qPCR experiments indicated that SbS did not affect RNA transcription levels of either E-cadherin or molecules involved in intercellular adhesion. Moreover, cycloheximide, an inhibitor of protein biosynthesis, did not counteract the effect of SbS on E-cadherin protein expression. It is now clear that the dynamic balance between endocytotic and recycling pathways, which deliver endocytosed or newly formed proteins to the plasma membrane, controls the expression of cell surface membrane E-cadherin and other adherens junction components. 41, 42 Therefore, this trafficking process is required for epithelial maintenance. 42, 43 Here, we reported that SbS enhances E-cadherin cell surface expression by preferentially regulating the traffic of endocytosed molecules. We revealed that: [i] Golgicide A, which arrests secretion of membrane-associated proteins at the endoplasmic reticulum -Golgi intermediate compartment, 44 did not counteract the effect of SbS. This strongly suggests that SbS does not regulate the traffic of newly synthesized E-cadherin.
[ii] SbS promotes a rapid relocalization of internalized E-cadherin to the cell surface membrane through vesicles located at the cell membrane periphery. Overall, our results argue in favor of SbS playing a role in E-cadherin trafficking by regulating the endosomal sorting machinery. Regulation of post-endocytic fate depends on whether E-cadherin is sorted to lysosomes for degradation or recycled back to the cell membrane. 45 Although our results emphasize the latter possibility, a role of SbS in sorting E-cadherin to the lysosomal compartment must also be considered.
E-cadherin trafficking occurs in membrane vesicles whose formation, transport and targeting is controlled by different Rab GTPases, including Rab4, Rab5 and Rab11A. 13, 19, 30, [45] [46] [47] [48] Moreover, E-cadherin recycling to the plasma membrane can occur either via a rapid pathway directly controlled by Rab4 or via recycling endosomes, which involves Rab11A. 30, 31 We reported here that SbS enhanced E-cadherin trafficking through Rab11A-dependent recycling endosomes. Our results indicate that: [i] SbS promotes Rab11A and E-cadherin colocalization in a proportion of vesicles located at the cell membrane periphery; however, we did not find any E-cadherin/Rab4 colocalization in vesicles; [ii] SbS failed to deliver endocytosed E-cadherin in vesicles located at the cell periphery in Rab11A-deficient cells. It has been suggested that Rab11A dysfunction correlates with intestinal disorders characterized by epithelial barrier dysfunction, including IBD. 33, 29 Moreover, Rab11A deletion was shown to activate inflammatory signaling pathways and overproduce cytokines, causing IBD in both mouse and Drosophilia enterocytes. 29 It is therefore tempting to speculate that SbS should be effective in the treatment of IBD by regulating E-cadherin trafficking through Rab11A-dependent processes. Nevertheless, activity of other Rab GTPases, including both Rab5 and Rab7, involved in targeting E-cadherin to lysosomes upon internalization, remains to be clarified in order to completely decipher the role of SbS in E-cadherin trafficking to the plasma membrane. Previous studies demonstrated that in calcium-depleted intestinal epithelial cells, E-cadherin could also be internalized into an unusual endosomal compartment, a unique Syntaxin-4-positive storage compartment that is distinct from Rab4-or Rab11-positive recycling endosomes. 49 We therefore cannot rule out that SbS accelerates E-cadherin trafficking from this additional storage compartment. Although E-cadherin plays a pivotal role in organizing adherens junctions, its function is regulated in part by p120 ctn, a cytoplasmic binding partner that directly regulates cadherin stability. 45, 50 Indeed, p120 ctn reduces cadherin endocytosis by directly binding E-cadherin and masking motifs necessary for endocytosis. 51 Our results, in accordance with a previous study, showed a partial downregulation and/or relocalization of p120 ctn from cell junctions to cytoplasm in IBD patients. 52 As observed for E-cadherin, SbS also enhances p120 ctn delivery to the plasma membrane, suggesting that SbS could regulate trafficking of p120 ctn as well as E-cadherin. This finding is of major importance, since p120 ctn has been reported to play essential roles in barrier function, epithelial homeostasis and survival in the gut.
Conclusion
In summary, our data clearly demonstrate that SbS enhances E-cadherin delivery to the cell surface through regulation of Rab11A-dependent recycling endosomes, leading to the restoration of enterocyte adherens junctions. The overall consequence of this process is the restoration and strengthening of intestinal barrier function. Importantly, these findings open new avenues toward uncovering novel options for prevention and therapy of diseases affecting intestinal permeability.
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